
Day 2 Recap: South Beach Symposium 2026
Key Takeaways
- Patient-centered endpoints, including mental health and quality-of-life measures, are increasingly essential for interpreting psoriasis trial value beyond traditional lesion-based metrics.
- Social media and AI are reshaping dermatologist–patient trust, demanding higher standards for transparency, data integrity, and responsible communication in public-facing clinical education.
Catch up on coverage from the second day of South Beach Symposium 2026.
To stay informed with the latest conference insights, follow us on social media and
Depth, Speed, and Durability: What Matters Most in Modern Clinical Trials
David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.
The Digital Dermatologist: Where Visibility Meets Responsibility
At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.
Doris Day, MD, on Redefining Anti-Aging in Dermatology
Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.
Balancing Molecular Tools With Clinical Judgment
Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.
Ablon's Alopecia and Aesthetic Best Practices
Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.
For more insights from SBS and beyond, check out our
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.











